Clinical trials: Polycystic Kidney, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease
High Water Intake in Polycystic Kidney Disease
DRINK is an open-label randomised controlled feasibility trial of high versus ad libitum water intake in ADPKD.
- Trial name
- DRINK (NCT02933268)
- Testing
- High water intake, Ad libitum water intake
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Canadian Medical Assessment of JINARC™ Outcomes Registry
This study is part of the Health Canada approval requirement for JINARC™ (tolvaptan) and is an observational, non-interventional study (NIS) describing the impact of tolvaptan on ADPKD-related burden of illness as measured with a…
- Trial name
- C-MAJOR (NCT02925221)
- Where
- 6 sites in Canada
- Volunteers
- 530 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
Autosomal Dominant Polycystic Kidney, Hypertension
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
People with autosomal dominant polycystic kidney disease (ADPKD) develop high blood pressure and kidney disease. Previous studies have shown that a commonly occurring chemical, nitric oxide (NO), is reduced in ADPKD, and may…
- Conditions
- Autosomal Dominant Polycystic Kidney, Hypertension, Endothelial Dysfunction
- Trial name
- BEET-PKD (NCT05401409)
- Testing
- Beetroot juice, Nitrate-depleted beetroot juice
- Where
- 2 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Western Sydney Local Health District
Kidney Transplant; Complications, Polycystic Kidney Diseases
Evaluation of Iliac and Renal Artery for Mechanism of Intracranial Aneurysm in ADPKD
ADPKD is the most common form of hereditary kidney disease and is known to occur in 1 of 400 to 1000 population in the U.S. ADPKD consists of 2.8% of patients receiving kidney transplantation in our center.
- Conditions
- Kidney Transplant; Complications, Polycystic Kidney Diseases, Aneurysm, Brain
- Trial name
- NCT03726463
- Testing
- Kidney transplantation
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Kidney, Polycystic, Autosomal Dominant
Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)
This phase II study examines the safety and efficacy of combination therapy for hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT00890279
- Testing
- Cilnidipine, Imidapril
- Where
- 9 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Autosomal Dominant Polycystic Kidney Disease
ADPKD Cohort Study
The purpose of this study is to find out if radiology tests of the kidneys as opposed to glomerular filtration (GFR) tests (GFR test - a lab test that measures kidney function) follow progression of polycystic kidney disease…
- Trial name
- NCT02084849
- Where
- United States
- Volunteers
- 624 people
- Sponsor
- Emory University
Polyuria, Autosomal Dominant Polycystic Kidney
Dietary Intervention in ADPKD on Tolvaptan
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder. Tolvaptan has been approved in Canada as a treatment for ADPKD.
- Trial name
- DIAT (NCT03858439)
- Testing
- Dietary
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McMaster University
Autosomal Dominant Polycystic Kidney Disease
Effect of the Aquaretic Tolvaptan on Nitric Oxide System
Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which stimulates V1-receptors in the vascular bed and…
- Trial name
- TOPO (NCT02527863)
- Testing
- Tolvaptan
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Regional Hospital Holstebro
Autosomal Dominant Polycystic Kidney, ADPKD
Analysis of Patients With Autosomal Dominant Polycystic Kidney
The main objective of the study is to establish a database of clinical data and genetic data of patients diagnosed with ADPKD, with particular focus on those who have undertaken a specific therapy (Tolvaptan or Octreotide)…
- Trial name
- NCT06759142
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101 study.
- Trial name
- NCT02616055
- Testing
- tesevatinib
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Kadmon Corporation, LLC
Autosomal Dominant Polycystic Kidney Disease
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
The Division of Kidney Urology and Hematology Disease (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) funded a cooperative agreement (UO1) for a consortium of participating clinical centers…
- Trial name
- CRISP II (NCT01039987)
- Where
- 5 sites in United States
- Volunteers
- 211 people
- Sponsor
- University of Pittsburgh
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.
- Trial name
- NCT07792408
- Testing
- VX-407, LNG/EE, NGM/EE
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autosomal Dominant Polycystic Kidney Disease, Glomerular Filtration Rate > 40 ml/Min
Effects of Somatostatin on ADPKD Heart
Autosomal dominant polycystic kidney disease (ADPKD) is associated with early onset hypertension and left ventricular (LV) hypertrophy.
- Trial name
- NCT02119013
- Testing
- Octeotride
- Volunteers
- 35 people
- Sponsor
- Federico II University
Polycystic Kidney, Type 1 Autosomal Dominant Disease, Polycystic Kidney, Type 2 Autosomal Dominant Disease
Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
Sirolimus (SIR) has lead to a reduction of overall kidney size, a decrease in cyst density and general tubular cell proliferation in animal models, and to a reduction of the increase in creatinine and blood urea nitrogen by 34…
- Trial name
- RAP (NCT02055079)
- Testing
- Sirolimus
- Where
- Austria
- Volunteers
- 68 people
- Sponsor
- Medical University of Vienna
ADPKD
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A mild reduction in food intake significantly inhibits renal cyst growth in mouse models of ADPKD. The underlying mechanism was unknown at the time.
- Trial name
- Keto-ADPKD (NCT04680780)
- Testing
- Ketogenic diet, 3-days water-fasting, Control
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- University of Cologne
Polycystic Liver Disease, Hepatomegaly
Lanreotide as Treatment of Polycystic Livers
To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney, Autosomal Dominant
- Trial name
- LOCKCYST (NCT00565097)
- Testing
- Lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 38 people
- Sponsor
- Radboud University Medical Center
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study
This is a no-profit, retrospective observational study involving real-world data (RWD), retrieved from ADPKD-related electronic health records stored at Mario Negri Institute IRCCS.
- Trial name
- SAILING-ADPKD (NCT07016282)
- Where
- 2 sites in Italy, Sweden
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease
Managing Depressive Symptoms in ADPKD
The purpose of this research is to evaluate the feasibility and effectiveness of Digital Neurotherapy (DNT) or Capacity Coaching (CC) for managing symptoms of depression and self reported pain in Autosomal Dominant Polycystic…
- Trial name
- NCT07745920
- Testing
- Mayo Clinic-Approved Education, Digital Neuropathy, Capacity Coaching
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide was shown in experimental studies to inhibit the cyst formation and growth in ADPKD models, while triptolide-containing formulation was revealed to potentially slow the disease progression in several proteinuric ADPKD…
- Trial name
- NCT02115659
- Testing
- Triptolide-Containing Formulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Changzheng Hospital
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
The general aim of this study in adult patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and severe renal insufficiency is to assess the safety and the efficacy of sirolimus (SRL) in slowing renal function…
- Trial name
- SIRENA-II (NCT01223755)
- Testing
- Sirolimus, conventional therapy
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- Mario Negri Institute for Pharmacological Research